RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx announced the first commercial clinical use of its RenovoCath device for treating sarcoma at CARTI Cancer Center, marking an expansion into solid tumors beyond its core pancreatic indication. The milestone demonstrates the device's versatility in delivering localized chemotherapy, with CARTI physicians citing the potential to reduce toxicity compared to systemic treatments.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.